Previous 10 | Next 10 |
One-year Pivotal Study Results from ARTISAN-SNM to be Presented at Plenary Session Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (“SNM”) devices for the...
Axonics Modulation Technologies (NASDAQ: AXNX ) revealed on Monday (September 9) that the US Food and Drug Administration has given the company seal of approval for its rechargeable sacral neuromodulation (SNM) device. Called the Axonics r-SNM® System, the rechargeable devic...
Company to host conference call and webcast at 9:00 am EDT Today Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) device for the t...
Nuvectra Corporation (NASDAQ: NVTR ) is a medical device company founded in 2008 that went public in March 2016. NVTR’s flagship product, Algovita, is a neurostimulator that is FDA approved for the treatment of chronic pain of the trunk (human torso) and limbs (reimbursable under exis...
Correvio Pharma (NASDAQ: CORV ) initiated with Overweight rating and $6 (193% upside) price target at Cantor Fitzgerald. More news on: Correvio Pharma Corp., InMode Ltd., MeiraGTx Holdings plc, Healthcare stocks news, Stocks on the move, , Read more ...
Axonics Modulation Technologies, Inc. (AXNX) Q2 2019 Results Earnings Conference Call August 05, 2019, 4:30 pm ET Company Participants Matt Clawson - Investor Relations, Practice Leader and Investor Relations at W2O Group Raymond Cohen - Chief Executive Officer Dan Dearen - Presi...
Axonics Modulation Technologies (NASDAQ: AXNX ): Q2 GAAP EPS of -$0.68 misses by $0.19 . More news on: Axonics Modulation Technologies, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, reported today financial results for the sec...
AEIS , AEL , ANSS , APLE , APU , ATSG , AVID , AWR , AXNX , BHF , BKD , BKH , BWXT , CAR , CBPO , CBT , CDEV , CLR , COHU , CSOD , CXW , CYH , CZR , DEI , DIOD , DOOR , DRH , EVBG , FRPT , FRTA , GPRE , HIIQ , HLIO , HPR , IFF , IPAR , ITRI , IVC , KLA...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction , today announced completion of 1-year follo...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
2024-06-19 23:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...